Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Drug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

Fineline Cube Jul 27, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...

Company Deals

CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease

Fineline Cube Jul 27, 2022

China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...

Company Deals R&D

HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration

Fineline Cube Jul 27, 2022

China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...

Company Deals

Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing

Fineline Cube Jul 27, 2022

Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic...

Company Deals

Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences

Fineline Cube Jul 27, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer...

Company Deals

Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development

Fineline Cube Jul 27, 2022

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a...

Company Drug

Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer

Fineline Cube Jul 27, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Deals

Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal

Fineline Cube Jul 26, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...

Company Drug

SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval

Fineline Cube Jul 26, 2022

SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...

Company Deals

Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development

Fineline Cube Jul 26, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell...

Company Medical Device

AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval

Fineline Cube Jul 26, 2022

US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical...

Company Drug

Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers

Fineline Cube Jul 26, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s...

Company Drug

Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study

Fineline Cube Jul 26, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Drug

Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors

Fineline Cube Jul 26, 2022

China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...

Company Drug

Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study

Fineline Cube Jul 26, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Deals

Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma

Fineline Cube Jul 26, 2022

China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...

Drug

Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan

Fineline Cube Jul 26, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...

Company Drug

GenFleet Therapeutics’ GFH018 Receives CTA Approval for Two Clinical Trials in China

Fineline Cube Jul 26, 2022

Shanghai-based biotech company GenFleet Therapeutics announced that two clinical trial applications (CTAs) for its drug...

Company Deals Drug

NMPA Approves Genuine Biotech’s Azvudine for COVID-19, Fosun Pharma Inks Licensing Deal

Fineline Cube Jul 26, 2022

China’s National Medical Products Administration (NMPA) has conditionally approved HeNan Genuine Biotech Co., Ltd’s azvudine...

Policy / Regulatory

Chinese Pharmacists Association Releases Draft VBP Drug Management Guidelines for Public Feedback

Fineline Cube Jul 26, 2022

The Chinese Pharmacists Association (CPA) has released the “National Volume-based Procurement (VBP) Drug Management Expert...

Posts pagination

1 … 686 687 688 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.